Thermo Fisher (TMO) is a publicly traded Healthcare sector company. As of May 20, 2026, TMO trades at $451.13 with a market cap of $164.26B and a P/E ratio of 24.62. TMO moved +0.93% today. Year to date, TMO is -26.08%; over the trailing twelve months it is +9.19%. Its 52-week range spans $385.46 to $643.99. Analyst consensus is strong buy with an average price target of $611.60. Rallies surfaces TMO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TMO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TMO recently traded at $451.13. Market cap is $164.26B. P/E ratio is 24.62. Revenue is $45.20B.
| Metric | Value |
|---|---|
| Price | $451.13 |
| Market Cap | $164.26B |
| P/E Ratio | 24.62 |
| EPS | $18.22 |
| Dividend Yield | 0.47% |
| 52-Week High | $643.99 |
| 52-Week Low | $385.46 |
| Volume | 2.42M |
| Avg Volume | 0 |
| Revenue (TTM) | $45.20B |
| Net Income | $6.87B |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.56B | $6.72B | $17.77 |
| 2024 | $42.88B | $6.34B | $16.58 |
| 2023 | $42.86B | $5.96B | $15.52 |
| 2022 | $44.91B | $6.96B | $17.75 |
17 analysts cover TMO: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $611.60.